XML 42 R28.htm IDEA: XBRL DOCUMENT
v3.25.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Accounting Policies [Abstract] |
SCHEDULE OF PURCHASE PRICE AND FINALIZED PURCHASE PRICE ALLOCATIONS | The following table summarizes the purchase price and finalized purchase price allocations relating to the acquisition: SCHEDULE OF PURCHASE PRICE AND FINALIZED PURCHASE PRICE ALLOCATIONS
Cash |  | $ | 2,500,000 |
Common Stock |  |  | 1,000,000 |
Total purchase consideration |  | $ | 3,500,000 |
Assets |  |  |  |
Net working capital (including cash) |  | $ | 912,000 |
Property and equipment |  |  | 326,000 |
Other assets |  |  | 8,000 |
Customer relationships |  |  | 700,000 |
Trade names and trademarks |  |  | 150,000 |
Goodwill |  |  | 1,404,000 |
Total net assets |  | $ | 3,500,000 |
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES | The following potentially dilutive securities have been excluded from the computations of weighted average shares of Common Stock outstanding as of December 31, 2024 and 2023, as they would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES
|  | As of December 31, |
|  | 2024 |  |  | 2023 |
Shares underlying options outstanding |  |  | 304,125 |  |  |  | 683,695 |
Shares underlying warrants outstanding |  |  | 12,298,124 |  |  |  | — |
Shares underlying unvested restricted stock outstanding |  |  | 349,057 |  |  |  | 4,649,952 |
Anti-dilutive securities |  |  | 12,951,306 |  |  |  | 5,333,647 |
SCHEDULE OF REVENUE RECOGNITION | SCHEDULE OF REVENUE RECOGNITION
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |
Patient service fees1 |  | $ | 8,175,670 |  |  | $ | 2,199,558 |
Histology service fees |  |  | 1,103,751 |  |  |  | 272,660 |
Medical director fees |  |  | 66,576 |  |  |  | 19,324 |
Department of Defense observational studies |  |  | 8,654 |  |  |  | 19,442 |
Other revenues |  |  | 7,371 |  |  |  | 21,515 |
Total net revenue |  | $ | 9,362,022 |  |  | $ | 2,532,499 |
1 | Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $516,000 and $35,000 for the years ended December 31, 2024 and 2023.
SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE | Property and equipment are carried at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the asset. Amortization of leasehold improvements is computed using the shorter of the lease term or estimated useful life of the asset. Additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. Useful lives of each asset class are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE
Asset Category |  | Useful Life
Computer equipment |  | 3-5 years
Computer software |  | 3 years
Equipment |  | 3-5 years
Furniture and fixtures |  | 5-7 years
Vehicles |  | 5 years
Leasehold improvements |  | Lesser of lease term or useful life
SCHEDULE OF INTANGIBLE ASSETS | SCHEDULE OF INTANGIBLE ASSETS
|  | 2024 |  |  | 2023 |
|  | December 31, |
|  | 2024 |  |  | 2023 |
Cost |  |  |  |  |  |  |  |
Goodwill |  | $ | 1,404,486 |  |  | $ | 1,404,486 |
Trade names and trademarks |  |  | 150,000 |  |  |  | 150,000 |
Customer relationships |  |  | 700,000 |  |  |  | 700,000 |
Cost |  |  | 2,254,486 |  |  |  | 2,254,486 |
Accumulated amortization |  |  |  |  |  |  |  |
Goodwill |  |  | — |  |  |  | — |
Trade names and trademarks |  |  | (10,694 | ) |  |  | (2,361 | )
Customer relationships |  |  | (64,167 | ) |  |  | (14,167 | )
Accumulated amortization |  |  | (74,861 | ) |  |  | (16,528 | )
Intangible assets, net |  | $ | 2,179,625 |  |  | $ | 2,237,958 |
SCHEDULE OF SEGMENT INFORMATION | SCHEDULE OF SEGMENT INFORMATION
|  | As of December 31, |
|  | 2024 |  |  | 2023 |
Net revenues: |  |  |  |  |  |  |  |
Diagnostic R&D |  | $ | 8,654 |  |  | $ | 19,442 |
Laboratory services |  |  | 9,353,368 |  |  |  | 2,513,057 |
Total net revenues |  |  | 9,362,022 |  |  |  | 2,532,499 |
Operating expenses: |  |  |  |  |  |  |  |
Diagnostic R&D |  |  | (1,782,882 | ) |  |  | (1,724,597 | )
Laboratory services |  |  | (9,946,452 | ) |  |  | (3,769,783 | )
General corporate activities |  |  | (6,586,133 | ) |  |  | (5,011,347 | )
Total operating loss |  |  | (8,953,445 | ) |  |  | (7,973,228 | )
Non-operating income (expense), net |  |  | (74,736 | ) |  |  | 57,210 |
Net loss before income taxes |  |  | (9,028,181 | ) |  |  | (7,916,018 | )
Income tax expense |  |  | (11,650 | ) |  |  | (20,993 | )
Net loss |  | $ | (9,039,831 | ) |  | $ | (7,937,011 | )

X
- Definition Property And Equipment Useful Life [Table Text Block] + References No definition available. + Details
Name: | BIAF_PropertyAndEquipmentUsefulLifeTableTextBlock
Namespace Prefix: | BIAF_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration